Thetis Pharmaceuticals Cancer Program to be Presented at the American Association of Cancer Research (AACR) Annual Meeting (4/5/23)

Preclinical proof-of-concept data for TP-317 presented at the special session on Targeting the Tumor Microenvironment (TME) in Drug Development

ESSEX, CT – (April 5, 2023) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing a first-in-class, oral small molecule Resolvin E1-based drug to treat cancer and chronic inflammatory diseases, today announced that preclinical proof-of-concept data for TP-317 will be highlighted in an oral presentation at the “Targeting the Tumor Microenvironment in Drug Development” special session at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023 in Orlando, Florida. An abstract for the presentation, titled “TP-317, a first-in-class resolvin E1 small molecule, potentiates the efficacy of immune checkpoint (ICI) inhibitors in ICI-resistant and ICI-sensitive tumors” can be viewed at this link.

"The oral presentation at this year's AACR Targeting the Tumor Microenvironment in Drug Development session is an exciting opportunity to showcase preclinical data for TP-317 as a potential first-in-class, myeloid-directed Resolvin E1 (RvE1) small molecule targeting solid tumors that negate the benefit of immune checkpoint inhibition by mounting a broad immune suppressive response, including abrogation of antigen processing in the TME", said John Parkinson, Chief Scientific Officer of Thetis Pharmaceuticals.

About TP-317
Overview: TP-317 is a patented small molecule drug that delivers RvE1, an endogenous lipid mediator that regulates immune homeostasis. Unlike anti-inflammatory drugs and anti-cancer agents that are immuno-suppressive, TP-317 activates innate and adaptive immune pathways to treat disease without compromising host-protective immunity.

Cancer Program: TP-317 is being developed as an adjunct to immune checkpoint inhibitors in refractory metastatic melanoma and advanced non-small-cell lung cancer (NSCLC), and as adjunct to second-line chemotherapy in pancreatic cancer. Preclinical studies with oral TP-317 have shown potent single-agent activity and enhanced efficacy when combined with immune checkpoint inhibitors or chemotherapy.

IBD Program: TP-317 is being developed as first-line, oral therapy for mild-to-moderate Crohn’s disease and as second-line, oral therapy for mild-to-moderate ulcerative colitis in patients who are not well controlled on 5-ASA or corticosteroids. TP-317 also has potential to treat moderate-to-severe IBD as adjunct therapy to standard-of-care biologics or oral immunomodulators. The anticipated high safety premium for TP-317 further supports early intervention in IBD and other immune disorders.

About Thetis Pharmaceuticals
Thetis is a biopharmaceutical company dedicated to improving the lives of patients suffering from cancer and chronic inflammatory diseases. Thetis’ proprietary HEALER™ technology enables the pharmaceutical development of Resolvins, overcoming the stability, manufacturing, and formulation hurdles that have limited their commercial development. Thetis is supported by venture capital investors, NIH, and leading private philanthropies, including the Helmsley Charitable Trust, the Crohn’s & Colitis Foundation, and the Kenneth Rainin Foundation.

Disclaimer
TP-317 is an investigational drug product that has not been approved by the U.S. Food and Drug Administration. 

Contact Information
For more information, please visit Thetis Pharmaceuticals’ website (www.thetispharma.com) or email us at info@thetispharma.com